This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2020.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2020
Title: Mattias Cv Carlsten: Innovator in Cancer Treatment
Introduction
Mattias Cv Carlsten is a prominent inventor based in Bethesda, MD (US). He has made significant contributions to the field of cancer treatment through his innovative research and patented technologies. His work focuses on enhancing the efficacy of natural killer (NK) cells in targeting tumors.
Latest Patents
Mattias Cv Carlsten holds a patent for "NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors." This patent discloses modified NK cells, compositions comprising these modified NK cells, and methods for treating tumors or hyperproliferative diseases in subjects. The modified NK cells include a heterologous nucleic acid molecule encoding a CD16 protein with a valine at amino acid position 158 (CD16-V158) and a heterologous nucleic acid molecule encoding a CCR7 protein. The methods described involve administering a composition comprising an anti-cancer monoclonal antibody alongside the modified NK cells to effectively treat tumors.
Career Highlights
Mattias Cv Carlsten is associated with the United States of America, as represented by the Secretary, Department of Health and Human Services. His work has been instrumental in advancing the understanding and application of NK cell therapies in oncology.
Collaborations
He collaborates with Richard W Childs, a fellow researcher in the field, to further explore the potential of NK cell modifications in cancer treatment.
Conclusion
Mattias Cv Carlsten's innovative work in modifying NK cells represents a significant advancement in cancer therapy. His contributions are paving the way for more effective treatments for patients suffering from tumors and hyperproliferative diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile